Academic Journal
Q1American Journal of Cardiovascular Drugs
About American Journal of Cardiovascular Drugs
American Journal of Cardiovascular Drugs is a scholarly journal published by its listed publisher. SCImago 2025 lists it in Q1, with an SJR of 0.952 and H-index of 66.
Coverage: 2001-2026. Research categories: Cardiology and Cardiovascular Medicine (Q1); Medicine (miscellaneous) (Q1); Pharmacology (medical) (Q1).
Verified field sources
- Journal Impact Factor: 3.2 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Source-backed journal facts
Topics in published research
Atrial Fibrillation Management and Outcomes; Lipoproteins and Cardiovascular Health; Antiplatelet Therapy and Cardiovascular Diseases; Heart Failure Treatment and Management; Blood Pressure and Hypertension Studies; Acute Myocardial Infarction Research.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
4,790.00 USD; 3,790.00 EUR; 2,990.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Beta-Blockers for the Treatment of Arrhythmias: Which Drug for Which Arrhythmia? A State-of-the-Art Narrative Review
Lucian Muresan, Gabriel Cismaru, Stefan Lucian Popa, Radu Rosu et al.
2026-09-21 · DOI: 10.1007/s40256-026-00828-2Temporal Trends and Predictors of P2Y12 Inhibitor Selection and Switching Following Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
Young Eun Shin, Arun Kumar, Anne Metzger, Patricia Wigle et al.
2026-09-21 · DOI: 10.1007/s40256-026-00827-3SGLT2 Inhibitors in Cardiovascular-Kidney-Metabolic Syndrome: Drugs Unifying Heart, Kidney, and Metabolism Pharmacotherapy
Valentina Okhovat, Kamela Lybeshari, Luigi X. Cubeddu, Genevieve Hale et al.
2026-09-15 · DOI: 10.1007/s40256-026-00829-1Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies
José Pablo Miramontes González
2026-08-31 · DOI: 10.1007/s40256-026-00825-5Vutrisiran in Transthyretin Amyloidosis: A Narrative Review
Kamela Lybeshari, Huy Pham, Genevieve Hale
2026-08-20 · DOI: 10.1007/s40256-026-00824-6The Impact of β-Blocker Therapy on Peak VO2 in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis
Juliana Giorgi, Pedro Gomes Batista, Milena dall Witt de Souza, Giulia Gaelzer et al.
2026-08-19 · DOI: 10.1007/s40256-026-00822-8Zilebesiran in Hypertension: Reversibility, Acute Illness, and Therapeutic Flexibility
Lucas Maciel de Almeida Corrêa, Gabriel Rian Mazur, Clara Belo Gamon Santiago, Alexandre de Assis Barbosa et al.
2026-08-17 · DOI: 10.1007/s40256-026-00823-7Evaluating the Impact of Stair Climbing on Cardiovascular Risk Reduction: A Systematic Review and Meta-analysis
Sophie Paddock, Rathna Veerni, U. Bhalraam, James Meng et al.
2026-08-13 · DOI: 10.1007/s40256-026-00811-xAntihypertensive Efficacy and Safety of Angiotensin Receptor Blockers (ARBs) with and without Inverse Agonism: A Systematic Review and Network Meta-analysis
Jing Liu, Jialu Geng, Jiakun Liu, Lei Hu et al.
2026-08-08 · DOI: 10.1007/s40256-026-00813-9Adherence and Healthcare Costs Associated with Single-vs Free-Pill Combination of Perindopril-Based Antihypertensive Medications: An 11-Year Follow-Up, Real-World Evidence
Gianluigi Savarese, Ana-Maria Vintila, Luca Degli Esposti, Melania Dovizio et al.
2026-08-07 · DOI: 10.1007/s40256-026-00818-4Comparative Effectiveness of Sacubitril/Valsartan Versus Sodium-Glucose Cotransporter 2 Inhibitors among Patients with Heart Failure with Reduced Ejection Fraction with or without Diabetes: A Cohort Study
Munaza Riaz, Steven M. Smith, David E. Winchester, Eric A. Dietrich et al.
2026-09 · DOI: 10.1007/s40256-026-00819-3When Methods Matter: An Umbrella Review of Lorundrostat and the Impact of Analytical Decisions on Reported Blood Pressure and Safety Outcomes
Zeyad Elariny, Omar Salem, Mohamad Ashraf Salaheldin, Adham Ahmed et al.
2026-09 · DOI: 10.1007/s40256-026-00817-5Aspirin Versus Clopidogrel as Single Antiplatelet Therapy After TAVI: A Propensity Score-Matched, Retrospective Analysis
Anastasios Apostolos, Konstantinos Konstantinou, Mohammed Allaf, Athanasios Sakalidis et al.
2026-09 · DOI: 10.1007/s40256-026-00815-7Empagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular Outcomes
Fatemeh Baharvand, Roxana Mehran, Francesca Maria Di Muro, Alieh Mohammadi et al.
2026-09 · DOI: 10.1007/s40256-026-00814-8Using Artificial Intelligence to Identify Patterns and Predictors of Adverse Drug Reactions in Cardiovascular Patients: A Comprehensive Narrative Review
Erfan Shahabinejad, Fatemeh Soflaei-Shahrbabak, Marzieh Gholami Shoa, Aida Azhdarimoghaddam et al.
2026-09 · DOI: 10.1007/s40256-026-00810-yFood Effects on the Pharmacokinetics of Single Dose and Steady-State Ralinepag, a Novel Oral Prostacyclin Agonist, in Healthy Volunteers
Daniel Lachant, Cristian E. Botta, George Giannakoulas, Natalie Patzlaff et al.
2026-09 · DOI: 10.1007/s40256-026-00807-7Combination Therapy of GLP-1 RA and SGLT2i in Patients with Established Heart Failure: A Systematic Review and Meta-Analysis of Observational Studies
Christopher Daniel Tristan, Irnizarifka Irnizarifka, Erlangga Masykur Kynaya, Mellisa Gani et al.
2026-09 · DOI: 10.1007/s40256-026-00812-wGLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis
Pedro Gomes Batista, Railla Raquel Albino dos Santos Silva, Marcela Vasconcelos Montenegro, Mushrin Malik et al.
2026-09 · DOI: 10.1007/s40256-026-00809-5Clinical Pharmacology of Plozasiran
Jessica Huston, Dontia Orey, Kelli Corona, Andrew Ashchi et al.
2026-09 · DOI: 10.1007/s40256-026-00808-6De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making
Navid Radfar, Dhir Gala, Harsh Singh, Juan Bello et al.
2026-09 · DOI: 10.1007/s40256-026-00806-8Reviews
Community Reviews
Version History
October 4, 2026 at 9:00 pm
October 2, 2026